The Globe and Mail reports in its Tuesday edition that Pfizer is scrapping its once-a-day experimental obesity pill because of concerns about liver safety, but will continue developing its other obesity pill, the twice-daily treatment danuglipron, as it races to rival the success of other weight-loss treatments. A Reuters dispatch to The Globe says that the company's shares dropped 3.6 per cent Monday as Pfizer said it would stop developing its therapy lotiglipron after patients who took the drug in clinical studies were shown to have elevated levels of liver enzymes. Pfizer chief executive officer Albert Bourla has said an obesity pill could eventually be a $10-billion-(U.S.)-a-year product for Pfizer. The company's shares have dropped 29 per cent so far this year as it works to develop its strategy past the COVID-19 vaccines and therapeutics that drove revenue and earnings for the past few years. Pfizer said it expects to finalize plans for the danuglipron late-stage program by the end of the year, and is also developing a once-daily, modified release version of that drug. Pfizer has been developing both pills in parallel, but had said all things being equal its preference would be for the once-daily lotiglipron.